| Arrowhead Pharma (ARWR) | |||
|---|---|---|---|
| 23.29 -0.49 (-2.06%) | 04-24 16:00 | ||
| Open: | 23.74 | Pre. Close: | 23.78 |
| High: | 23.74 | Low: | 22.89 |
| Volume: | 813,628 | Market Cap: | 2,886(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 31.31 One year: 34.96 |
| Support: | Support1: 21.75 Support2: 18.10 |
| Resistance: | Resistance1: 26.81 Resistance2: 29.93 |
| Pivot: | 24.38  |
| Moving Averages: | MA(5): 23.19  MA(20): 25.20 MA(100): 29.64 MA(250): 30.57 |
| MACD: | MACD(12,26): -1.56 Signal(12,26,9): -1.57 |
| %K %D: | %K(14,3): 35.42 %D(3): 27.57 |
| RSI: | RSI(14): 35.81 |
| 52-Week: | High: 42.48 Low: 20.67 Change(%): -34.4 |
| Average Vol(K): | 3-Month: 1283 10-Days: 930 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 23.768 - 23.917 | 23.917 - 24.022 |
| Low: | 22.541 - 22.725 | 22.725 - 22.854 |
| Close: | 23.047 - 23.318 | 23.318 - 23.509 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARWR ] has closed above bottom band by 29.3%. Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 123.90 |
| % Held by Insiders | 118950000.00 |
| % Held by Institutions | 4.49 |
| Shares Short (K) | 8840 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -285350016.000 |
| Book Value (p.s.) | |
| Profit Margin | -163.32 |
| Operating Margin | -3.00 |
| Return on Assets (ttm) | 845.3 |
| Return on Equity (ttm) | -24.7 |
| Qtrly Rev. Growth | 181740000.0 |
| Gross Profit (p.s.) | -130.972 |
| Sales Per Share | -147.556 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -2.77 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -196.21 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | -1.16 |
| Price to Book value | |
| Price to Sales | -0.16 |
| Price to Cash Flow | 11.25 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 8870000.000 |
